Cipla informs about disclosure

11 Apr 2025 Evaluate
Pursuant to the provisions of Regulation 30 read with Schedule III Part A Para B of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024, Cipla has informed that the Company has received final approval from the United States Food and Drug Administration (‘USFDA’) for the Abbreviated New Drug Application (‘ANDA’) submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial (‘Protein-bound Paclitaxel’) on 10th April, 2025.

The above information is a part of company’s filings submitted to BSE.

Cipla Share Price

1341.10 12.05 (0.91%)
20-Feb-2026 12:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.50
Dr. Reddys Lab 1288.70
Cipla 1341.10
Zydus Lifesciences 902.40
Lupin 2233.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×